Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Overview

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Full Title of Study: “A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Sequential Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: December 2020

Interventions

  • Drug: JPI-289 Low-dose
    • JPI-289 Low dose will be intravenously administered during 24 hours
  • Drug: JPI-289 High-dose
    • JPI-289 High dose will be intravenously administered during 24 hours
  • Drug: Placebo
    • Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours

Arms, Groups and Cohorts

  • Experimental: Low-dose group
    • JPI-289 Low dose or placebo
  • Experimental: High-dose group
    • JPI-289 High dose or placebo
  • Placebo Comparator: Placebo group
    • Same dosage of JPI-289 low and high dose

Clinical Trial Outcome Measures

Primary Measures

  • Infact growth ratio from baseline
    • Time Frame: 4 days from baseline

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects with acute ischemic stroke, aging ≥ 19 – Confirmed to have acute anterior circulation cerebral artery occlusion in intracranial internal carotid artery (IICA) or middle cerebral artery (MCA) M1 segment by CT or MR angiography. – National Institutes of Health Stroke Scale(NIHSS) is 6~30 before endovascular recanalization therapy (ERT) – Subject who is reperfused with 2b or 3 stages of thrombolysis in cerebral infarction (TICI) (However, if angiography is conducted for thrombectomy after IV tPA treatment and the effect of tPA results in TICI 2b-3 reperfusion, the subject can participate) – Subject who can administer IP within 6.5 hrs of symptom development – Subject who can administer IP within 30 min of vascular reperfusion – Subject who can evaluate MRI within 90 min of vascular reperfusion Exclusion Criteria:

  • Subject who is contraindicated for endovascular recanalization – Subject who has hypersensitivity to contrast agent or component of investigational product – Prohibited or unable to perform MRI test – Medical history that is related to bleeding – History of hemorrhagic stroke within 6 months of study participation – Subjects with chronic liver disorder – Kidney disorder (Serum creatinine > 3 mg/dL) – Life expectancy is less than 3 months due to concomitant disease other than stroke – Pregnant or lactating women – Those who have taken tirofiban (anticoagulant agent) during endovascular recanalization therapy – Those who have taken other investigational drugs and/or medical instruments 12 weeks prior to screening – Subject is unable to be followed up – Subject is deemed unable to participate the study in the opinion of the investigator.

Gender Eligibility: All

Minimum Age: 19 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Jeil Pharmaceutical Co., Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Byung Woo Yoon, MD., PhD, bwyoon@snu.ac.kr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.